Grants and Contributions:

Back to search
Title:
Development and Optimization of Novel Chimeric Antigen Receptor NK-cell Therapeutics for B-Cell Malignancy and Solid Tumors
Agreement Number:
986689
Agreement Value:
$200,000.00
Agreement Date:
Feb 1, 2022 - Jan 31, 2024
Description:
Even though CAR-T therapies show dramatic efficacy in inducing remission of cancers, their high cost and toxicity remain significant issues. Upon infusion of the T cells to a foreign host, the TCR reacts to the foreign MHC and induces graft versus host disease (GvHD), making it challenging to generate off-the-shelf, allogeneic therapy that can be given universally to genetically unrelated recipients. The GvHD often induces severe side effects, such as cytokine release syndrome (CRS) and neurotoxicity. The team hypothesize that CAR-NK cells will provide potent and safe immunotherapy for patients with hematological malignancies and solid tumors, which often do not respond to conventional therapies and current immunotherapies. In addition, the team reasons that advancing the technology of utilizing iPSCs-derived CAR-NK cells will facilitate the development of a more affordable and accessible off-the-shelf cellular cancer therapy. For this, the team will tackle the following questions to advance CAR-NK cell therapy to a clinical trial.
Organization:
National Research Council Canada
Expected Results:

In the short term, anticipated outcomes will be strengthened collaborations across industry, academia, and government to support research excellence. In the medium term, anticipated outcomes will be the development of new and potentially disruptive technologies with collaborators. In the long term, find collaborative solutions to public policy challenges and create stronger innovation systems.

Location:
Ottawa, Ontario, CA K1N 6N5
Reference Number:
172-2021-2022-Q4-986689
Agreement Type:
Grant
Report Type:
Grants and Contributions
Recipient Business Number:
119278877
Recipient Type:
Academia
Recipient's Legal Name:
University of Ottawa
Federal Riding Name:
Ottawa–Vanier
Federal Riding Number:
35078
Program:
Collaborative Science, Technology and Innovation Program - Collaborative R&D Initiatives
Program Purpose:

Collaborate on multiparty research and development programs to catalyze transformative, high-risk, high-reward research with the potential for game-changing scientific discoveries and technological breakthroughs in priority areas.

NAICS Code:
541710